DNTH vs FCX · rev $17.8M vs P/E 38, rev $13.26B
Dianthus Therapeutics Inc. (DNTH) versus Freeport-McMoran Copper & Gold Inc (FCX) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Latest reported DNTH revenue for 2026-06-30 was $17.8M. Net income was -$91.0M. DNTH currently screens at market cap $4.40B.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
DNTH currently screens at market cap $4.40B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Not investment advice. Open the DNTH and FCX stock pages for the full models.
Not investment advice.